Pharmaceutical - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

151 to 175 of 401 results

UK’s NICE says yes to Alimera’s Iluvien

27-11-2013

In final guidance published this morning by UK drugs watch dog the National Institute for Health and…

Alimera SciencesDiabetesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

US FDA eases restrictions on GSK diabetes drug Avandia

US FDA eases restrictions on GSK diabetes drug Avandia

26-11-2013

The US Food and Drug Administration yesterday (November 25) lifted some severe limitations on the prescribing…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA

25-11-2013

It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

EMA Committee backs Novo Nordisk’s NovoRapid PumpCart

EMA Committee backs Novo Nordisk’s NovoRapid PumpCart

22-11-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

DiabetesEuropeNovo NordiskNovoRapidPharmaceuticalRegulationRoche

Eli Lilly to invest further $700 million to boost insulin production

Eli Lilly to invest further $700 million to boost insulin production

14-11-2013

US pharma major Eli Lilly plans to invest more than $700 million to enhance its global insulin manufacturing…

DiabetesEli LillyFinancialPharmaceuticalProductionResearch

Kyowa Hakko drops Ph II study of bardoxolone

11-11-2013

Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating…

DiabetesKyowa Hakko KirinNephrology and HepatologyPharmaceuticalReata PharmaceuticalsResearch

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Eylea filed for EU and US approval in diabetic macular edema

Eylea filed for EU and US approval in diabetic macular edema

07-11-2013

US biotech firm Regeneron Pharmaceuticals says its partner German drug major Bayer has submitted an application…

BayerDiabetesEuropeEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds

06-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Novo Nordisk gains US FDA approval for FlexTouch insulin pens

Novo Nordisk gains US FDA approval for FlexTouch insulin pens

03-11-2013

Danish insulin giant Novo Nordisk announced on Friday that the US Food and Drug Administration has approved…

DiabetesFlexTouchLevemirNorth AmericaNovo NordiskNovoRapidPharmaceuticalRegulation

Novo Nordisk nine-month sales up 13%; takes larger diabetes market share

Novo Nordisk nine-month sales up 13%; takes larger diabetes market share

31-10-2013

Danish insulin giant Novo Nordisk reported sales of 61.9 billion ($11.3 billion) Danish kroner in the…

DiabetesFinancialNovo NordiskPharmaceutical

Novo Nordisk recalls some NovoMix 30 insulin products in Europe

Novo Nordisk recalls some NovoMix 30 insulin products in Europe

27-10-2013

Danish insulin giant Novo Nordisk said on Friday that it is recalling certain batches of its prefilled…

DiabetesEuropeNovo NordiskNovoMixPharmaceuticalRegulation

Chinese, European drugmakers strike $500 million-plus deal

25-10-2013

An agreement worth more than $500 million between privately-held Swiss/Greek pharmaceutical and clinical…

DiabetesEuropeFochon PharmaFosun PharmaLicensingPharmaceuticalResearchSellas Life Sciences

Type 2 diabetes market to reach $38.8 billion by 2019

25-10-2013

The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal

22-10-2013

PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show

05-10-2013

Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

DPP-IV inhibitors use in newly-diagnosed type 2 diabetes patients

03-10-2013

Through analysis of US longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors…

DiabetesMarkets & MarketingNorth AmericaPharmaceutical

151 to 175 of 401 results

Back to top